Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

avera mckennan hospital - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 5 mg

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

kaiser foundation hospitals - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

carilion materials management - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

roerig - trovafloxacin mesylate (unii: 0p1lko80wn) (trovafloxacin - unii:9f388j00uk) - tablet, film coated - 100 mg - trovan is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration .) nosocomial pneumonia caused by escherichia coli, pseudomonas aeruginosa, haemophilus influenzae , or staphylococcus aureus . as with other antimicrobials, where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. community acquired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, klebsiella pneumoniae, staphylococcus aureus, mycoplasma pneumoniae, moraxella catarrhalis, legionella pneumophila, or chlamydia pneumoniae . complicated intra-abdominal infections, including post-surgical infections caused by escherichia coli, bacteroides fragilis, vir

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg - bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. bromocriptine mesylate tablet and capsule therapy is indicated in the treatment of acromegaly. bromocriptine therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for several yea

Canada - engleză - Health Canada

apotex inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents

Canada - engleză - Health Canada

pharmascience inc - busulfan - solution - 6mg - busulfan 6mg - antineoplastic agents

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

fresenius kabi usa, llc - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli.  it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa .  this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli.  to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to t

Canada - engleză - Health Canada

eugia pharma inc. - busulfan - solution - 60mg - busulfan 60mg

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

monarch pharmaceuticals ireland - quinupristin dalfopristin - pdr for soln for infusion - 150mg/350m milligram